News
| 3 min read
Tariff-free US access and pricing reforms give the UK a potential edge in an uncertain global market.
| 4 min read
Without standardized, strain-level analysis, and clinically meaningful benchmarks, microbiome science will struggle to move from research into routine care.
| 4 min read
As the FDA shifts toward nonclinical methods, scientists weigh whether alternative technologies can match the predictive power of animal studies.
| 9 min read
Industry leaders predict this year will be shaped by AI-driven discovery, human-relevant safety testing, and tighter capital discipline.
| 3 min read
By combining human-derived data with AI-driven discovery, the partnership seeks to tackle Parkinson’s disease heterogeneity and improve target selection.
| 4 min read
Enzymes once viewed as rigid specialists are now being repurposed as modular tools, revealing latent chemical capabilities and enabling new approaches to molecule construction.
| 4 min read
Alzheimer’s diagnosis tests, AI-designed DNA circuits, bacterial insights, and more led the news this week.
| 5 min read
While faster reviews could bring life-saving treatments to patients sooner, compressed timelines could also limit regulatory scrutiny and strain FDA resources.
| 4 min read
LYMPHIR delivers targeted therapy for a rare and incurable form of skin lymphoma while opening doors for broader immuno-oncology applications.
| 4 min read
Combining unified data architecture with standards-based hardware allows pharma companies to scale processes faster and more reliably.
| 4 min read
Eli Lilly’s oral orforglipron and Novo Nordisk’s higher-dose WeGovy could be approved on an extremely accelerated timeline.
| 2 min read
The approach pairs ultrasound-induced tumor cell death with real-time antigen capture to drive both local and systemic immune responses.
